Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis
Background New antiretroviral therapy (ART) regimens for HIV could improve clinical
outcomes for patients. To inform global guidelines, we aimed to assess the comparative …
outcomes for patients. To inform global guidelines, we aimed to assess the comparative …
Tenofovir nephrotoxicity: 2011 update
B Fernandez-Fernandez… - AIDS research and …, 2011 - Wiley Online Library
Tenofovir is an acyclic nucleotide analogue reverse‐transcriptase inhibitor structurally
similar to the nephrotoxic drugs adefovir and cidofovir. Tenofovir is widely used to treat HIV …
similar to the nephrotoxic drugs adefovir and cidofovir. Tenofovir is widely used to treat HIV …
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society–USA panel
SM Hammer, JJ Eron, P Reiss, RT Schooley… - Jama, 2008 - jamanetwork.com
Context The availability of new antiretroviral drugs and formulations, including drugs in new
classes, and recent data on treatment choices for antiretroviral-naive and-experienced …
classes, and recent data on treatment choices for antiretroviral-naive and-experienced …
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a …
CJ Cohen, J Andrade-Villanueva, B Clotet, J Fourie… - The Lancet, 2011 - thelancet.com
Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine
(TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had equivalent sustained efficacy …
(TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had equivalent sustained efficacy …
The design of drugs for HIV and HCV
ED Clercq - Nature reviews Drug discovery, 2007 - nature.com
Since the discovery of the human immunodeficiency virus (HIV) in 1983, dramatic progress
has been made in the development of novel antiviral drugs. The HIV epidemic fuelled the …
has been made in the development of novel antiviral drugs. The HIV epidemic fuelled the …
Tenofovir‐associated renal and bone toxicity
CLN Woodward, AM Hall, IG Williams, S Madge… - HIV …, 2009 - Wiley Online Library
Objectives The aims of the study were to describe the clinical presentation and renal and
bone abnormalities in a case series of HIV‐infected patients receiving treatment with …
bone abnormalities in a case series of HIV‐infected patients receiving treatment with …
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo …
A Lazzarin, T Campbell, B Clotet, M Johnson… - The Lancet, 2007 - thelancet.com
Background TMC125 (etravirine) is a non-nucleoside reverse-transcriptase inhibitor
(NNRTI) with activity against NNRTI-resistant HIV-1 in phase IIb trials. The aim of DUET-2 is …
(NNRTI) with activity against NNRTI-resistant HIV-1 in phase IIb trials. The aim of DUET-2 is …
Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy
M Goicoechea, S Liu, B Best, S Sun… - The Journal of …, 2008 - academic.oup.com
Background. Plasma concentrations of tenofovir increase when the drug is coadministered
with some ritonavirboosted protease inhibitors (PI/r). We hypothesized that tenofovir …
with some ritonavirboosted protease inhibitors (PI/r). We hypothesized that tenofovir …
The lifetime medical cost savings from preventing HIV in the United States
BR Schackman, JA Fleishman, AE Su… - Medical care, 2015 - journals.lww.com
Objective: Enhanced HIV prevention interventions, such as preexposure prophylaxis for high-
risk individuals, require substantial investments. We sought to estimate the medical cost …
risk individuals, require substantial investments. We sought to estimate the medical cost …
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment
RH Haubrich, SA Riddler, AG DiRienzo, L Komarow… - Aids, 2009 - journals.lww.com
Background: The metabolic effects of initial therapy for HIV-1 infection are important
determinants of regimen selection. Methods: Open-label study in 753 subjects randomized …
determinants of regimen selection. Methods: Open-label study in 753 subjects randomized …